全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS ONE  2014 

Identification of a Circulating MicroRNA Signature for Colorectal Cancer Detection

DOI: 10.1371/journal.pone.0087451

Full-Text   Cite this paper   Add to My Lib

Abstract:

Prognosis of patients with colorectal cancer (CRC) is generally poor because of the lack of simple, convenient, and noninvasive tools for CRC detection at the early stage. The discovery of microRNAs (miRNAs) and their different expression profiles among different kinds of diseases has opened a new avenue for tumor diagnosis. We built a serum microRNA expression profile signature and tested its specificity and sensitivity as a biomarker in the diagnosis of CRC. We also studied its possible role in monitoring the progression of CRC. We conducted a two phase case-control test to identify serum miRNAs as biomarkers for CRC diagnosis. Using quantitative reverse transcription polymerase chain reactions, we tested ten candidate miRNAs in a training set (30 CRCs vs 30 controls). Risk score analysis was used to evaluate the diagnostic value of the serum miRNA profiling system. Other independent samples, including 83 CRCs and 59 controls, were used to validate the diagnostic model. In the training set, six serum miRNAs (miR-21, let-7g, miR-31, miR-92a, miR-181b, and miR-203) had significantly different expression levels between the CRCs and healthy controls. Risk score analysis demonstrated that the six-miRNA-based biomarker signature had high sensitivity and specificity for distinguishing the CRC samples from cancer-free controls. The areas under the receiver operating characteristic (ROC) curve of the six-miRNA signature profiles were 0.900 and 0.923 for the two sets of serum samples, respectively. However, for the same serum samples, the areas under the ROC curve used by the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) were only 0.649 and 0.598, respectively. The expression levels of the six serum miRNAs were also correlated with CRC progression. Thus, the identified six-miRNA signature can be used as a noninvasive biomarker for the diagnosis of CRC, with relatively high sensitivity and specificity.

References

[1]  Garcia-Bilbao A, Armananzas R, Ispizua Z, Calvo B, Alonso-Varona A, et al. (2012) Identification of a biomarker panel for colorectal cancer diagnosis. BMC Cancer 12: 43. doi: 10.1186/1471-2407-12-43
[2]  Murakoshi Y, Honda K, Sasazuki S, Ono M, Negishi A, et al. (2011) Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci 102: 630–638. doi: 10.1111/j.1349-7006.2010.01818.x
[3]  O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420–1425. doi: 10.1093/jnci/djh275
[4]  Burch J, Soares-Weiser K, St John D, Duffy S, Smith S, et al. (2007) Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. Journal of Medical Screening 14: 132–137.
[5]  Hewitson P, Glasziou P, Irwig L, Towler B, Watson E (2007) Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 1. doi: 10.1002/14651858.cd001216.pub2
[6]  Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, et al. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348–1360. doi: 10.1016/j.ejca.2007.03.021
[7]  Duttagupta R, Jones KW (2013) The curious case of miRNAs in circulation: potential diagnostic biomarkers? Wiley Interdiscip Rev RNA 4: 129–138. doi: 10.1002/wrna.1149
[8]  Stefani G, Slack FJ (2008) Small non-coding RNAs in animal development. Nature Reviews Molecular Cell Biology 9: 219–230. doi: 10.1038/nrm2347
[9]  Wang Q, Huang Z, Ni S, Xiao X, Xu Q, et al. (2012) Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One 7: e44398. doi: 10.1371/journal.pone.0044398
[10]  Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513–10518. doi: 10.1073/pnas.0804549105
[11]  Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW (2011) Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 6: e20769. doi: 10.1371/journal.pone.0020769
[12]  Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997–1006. doi: 10.1038/cr.2008.282
[13]  Nugent M, Miller N, Kerin MJ (2011) MicroRNAs in colorectal cancer: function, dysregulation and potential as novel biomarkers. Eur J Surg Oncol 37: 649–654. doi: 10.1016/j.ejso.2011.05.005
[14]  Liu R, Zhang C, Hu Z, Li G, Wang C, et al. (2011) A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47: 784–791. doi: 10.1016/j.ejca.2010.10.025
[15]  Chen X, Hu Z, Wang W, Ba Y, Ma L, et al. (2012) Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130: 1620–1628. doi: 10.1002/ijc.26177
[16]  Corte H, Manceau G, Blons H, Laurent-Puig P (2012) MicroRNA and colorectal cancer. Dig Liver Dis 44: 195–200. doi: 10.1016/j.dld.2011.10.010
[17]  Li J, Wang Y, Yu W, Chen J, Luo J (2011) Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 406: 70–73. doi: 10.1016/j.bbrc.2011.01.111
[18]  Wang F, Zheng Z, Guo J, Ding X (2010) Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol 119: 586–593. doi: 10.1016/j.ygyno.2010.07.021
[19]  Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108: 5003–5008. doi: 10.1073/pnas.1019055108
[20]  Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, et al. (2010) Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 5: e13515. doi: 10.1371/journal.pone.0013515
[21]  Liu H, Zhu L, Liu B, Yang L, Meng X, et al. (2012) Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 316: 196–203. doi: 10.1016/j.canlet.2011.10.034
[22]  Liu J, Gao J, Du Y, Li Z, Ren Y, et al. (2012) Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131: 683–691. doi: 10.1002/ijc.26422
[23]  Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, et al. (2013) Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. British Journal of Cancer 108: 644–652.
[24]  Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al. (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106: 4402–4407. doi: 10.1073/pnas.0813371106
[25]  Wang S, Li Q, Wang K, Dai Y, Yang J, et al. (2013) Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol 15: 849–854. doi: 10.1007/s12094-013-1014-4
[26]  Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, et al. (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032–1046. doi: 10.1016/j.cell.2009.03.047
[27]  Zhang Y, Guo J, Li D, Xiao B, Miao Y, et al. (2010) Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Medical Oncology 27: 685–689. doi: 10.1007/s12032-009-9269-x
[28]  Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, et al. (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126: 1166–1176. doi: 10.1002/ijc.24827
[29]  Li Z, Gu X, Fang Y, Xiang J, Chen Z (2012) microRNA expression profiles in human colorectal cancers with brain metastases. Oncol Lett 3: 346–350. doi: 10.3892/ol.2011.497
[30]  Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA (2010) Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 70: 5147–5154. doi: 10.1158/0008-5472.can-10-0410
[31]  Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z, et al. (2011) microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem 286: 10725–10734. doi: 10.1074/jbc.m110.165654
[32]  Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, et al. (2010) Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 60: 351–357. doi: 10.1111/j.1440-1827.2010.02526.x
[33]  Nilsson S, Moller C, Jirstrom K, Lee A, Busch S, et al. (2012) Downregulation of miR-92a Is Associated with Aggressive Breast Cancer Features and Increased Tumour Macrophage Infiltration. Plos One 7. doi: 10.1371/journal.pone.0036051
[34]  Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, et al. (2009) miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors. J Neurooncol 93: 325–332. doi: 10.1007/s11060-009-9797-4
[35]  Shi L, Cheng Z, Zhang J, Li R, Zhao P, et al. (2008) hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 1236: 185–193. doi: 10.1016/j.brainres.2008.07.085

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133